By Scientia Professor Vlado Perkovic

Conference Abstracts

SCIRICA B; BUSE JB; CATARIG AM; JEPPESEN OK; LINCOFF AM; MCGUIRE D; PERKOVIC V; PRATLEY R; STENSEN S; TRAN MC; RYAN D, 2026, '1696-P: Effect of Semaglutide on COVID-19–Related Complications and All-Cause Death: Pooled Analyses of the SELECT, FLOW, and SOUL Trials', in Diabetes, American Diabetes Association, Vol. 75, http://dx.doi.org/10.2337/db26-1696-p

Rizk D; Perkovic V; Kashihara N; Maes B; Rovin B; Trimarchi H; Zhang H; Desai M; Monaco L; Magirr A; Govan L; Hach T; Barratt J, 2026, 'THE APPLAUSE-IGAN TRIAL OF IPTACOPAN: FINAL 24-MONTH RESULTS', in AMERICAN JOURNAL OF KIDNEY DISEASES, W B SAUNDERS CO-ELSEVIER INC, LA, New Orleans, Vol. 87, pp. S7 - S8, presented at National-Kidney-Foundation Spring Clinical Meetings (SCM), LA, New Orleans, 06 May 2026 - 10 May 2026

Barratt J; Huang M; Hafkin J; Lohrmann E; Xia J; George V; Perkovic V, 2026, 'HYPOGAMMAGOBULINEMIA AND INFECTION RISK IN AN INTERIM ANALYSIS OF THE PHASE 3 VISIONARY TRIAL OF SIBEPRENLIMAB IN IGA NEPHROPATHY', in AMERICAN JOURNAL OF KIDNEY DISEASES, W B SAUNDERS CO-ELSEVIER INC, Vol. 87, pp. S153 - S153

Rizk D; Jhaveri KD; Workeneh B; Zhang Z; Hafkin J; Shah L; Fajardo C; Lafayette R; Perkovic V, 2026, 'IMPACT OF SGLT2I USE ON SIBEPRENLIMAB OUTCOMES IN IGA NEPHROPATHY (GAN SUBGROUP ANALYSIS FROM THE PHASE 3 VISIONARY TRIAL INTERIM ANALYSIS', in AMERICAN JOURNAL OF KIDNEY DISEASES, W B SAUNDERS CO-ELSEVIER INC, Vol. 87, pp. Ss167 - S167

Rizk D; Cheung CK; Kooienga L; Jhaveri KD; Zhang Z; Hafkin J; Pinto C; Lafayette R; Perkovic V, 2026, 'SIBEPRENLIMAB IN IGA NEPHROPATHY: ASSESSMENT OF TARGET PROTEINURIA THRESHOLDS IN THE PHASE 3 VISIONARY TRIAL INTERIM ANALYSIS', in AMERICAN JOURNAL OF KIDNEY DISEASES, W B SAUNDERS CO-ELSEVIER INC, Vol. 87, pp. S166 - S166

Zan J; Wong MG; Kim D; Shi S; Monaghan H; Perkovic V; Lv J; Zhang H, 2025, '#2009 Impact of systemic glucocorticoids on Gd-IgA1 levels in Immunoglobulin A Nephropathy: insights from the TESTING trial', in Nephrology Dialysis Transplantation, Oxford University Press (OUP), Vol. 40, pp. gfaf116.0437, http://dx.doi.org/10.1093/ndt/gfaf116.0437

Kim D; Woodward M; Lv J; Hladunewich M; Jha V; Hooi LS; Monaghan H; Perkovic V; Zhang H; Wong MG, 2025, '#745 Sex differences across treatment response to corticosteroids and kidney outcomes in IgA nephropathy: insights from the TESTING trial', in Nephrology Dialysis Transplantation, Oxford University Press (OUP), Vol. 40, pp. gfaf116.0351, http://dx.doi.org/10.1093/ndt/gfaf116.0351

Barratt J; Rizk D; Zhang H; Maes B; Kashihara N; Rovin B; Trimarchi H; Kollins D; Desai M; Papachristofi O; Koukouli E; Perkovic V, 2025, 'Effect of iptacopan discontinuation on proteinuria and complement biomarkers in patients with immunoglobulin A nephropathy (IgAN): a post hoc analysis from a Phase II trial', in NEPHROLOGY DIALYSIS TRANSPLANTATION, OXFORD UNIV PRESS, Vol. 40, http://dx.doi.org/10.1093/ndt/gfaf116.030

Perkovic V; Kollins D; Papachristofi O; Hach T; Jacinto-Sanders S; Merkel T; Renfurm R; Rizk DV, 2024, '#456 Efficacy and safety of iptacopan in patients with primary IgA nephropathy: interim analysis results of the Phase 3 APPLAUSE-IgAN study', in Nephrology Dialysis Transplantation, Oxford University Press (OUP), Vol. 39, pp. gfae069-0141-456, http://dx.doi.org/10.1093/ndt/gfae069.141

Rizk DV; Kollins D; Papachristofi O; Hach T; Jacinto-Sanders S; Merkel T; Renfurm R; Perkovic V, 2024, 'EFFICACY AND SAFETY OF IPTACOPAN IN PATIENTS WITH IGA NEPHROPATHY (IGAN): INTERIM ANALYSIS (IA) OF THE PHASE 3 APPLAUSE-IGAN STUDY', in AMERICAN JOURNAL OF KIDNEY DISEASES, W B SAUNDERS CO-ELSEVIER INC, SWEDEN, Stockholm, Vol. 83, pp. 699 - 700, presented at 61st Congress of European-Renal-Association (ERA), SWEDEN, Stockholm, 23 May 2024 - 26 May 2024

Perkovic V; Kollins D; Papachristofi O; Hach T; Jacinto-Sanders S; Merkel T; Renfurm R; Rizk DV, 2024, 'Efficacy and safety of iptacopan in patients with primary IgA nephropathy: interim analysis results of the Phase 3 APPLAUSE-IgAN study', in NEPHROLOGY DIALYSIS TRANSPLANTATION, OXFORD UNIV PRESS, SWEDEN, Stockholm, Vol. 39, pp. I255 - I256, presented at 61st Congress of European-Renal-Association (ERA), SWEDEN, Stockholm, 23 May 2024 - 26 May 2024

Rovin B; Barratt J; Murphy E; Geletka R; Komers R; Perkovic V, 2024, 'SPARSENTAN (SPAR) SHOWS CLINICALLY MEANINGFUL TREATMENT EFFECTS VS IRBESARTAN (IRB) IN PATIENTS WITH IGA NEPHROPATHY (IGAN) IN THE PHASE 3 PROTECT TRIAL', in AMERICAN JOURNAL OF KIDNEY DISEASES, W B SAUNDERS CO-ELSEVIER INC, CA, Long Beach, Vol. 83, pp. S114 - S114, presented at Spring Clinical Meeting of the National Kidney Foundation, CA, Long Beach, 14 May 2024 - 18 May 2024

Ha J; Fletcher R; Yu J; Arnott C; Jun M; Perkovic V; Badve S; Neuen B, 2024, 'ALBUMINURIA, KIDNEY FUNCTION AND HEART FAILURE IN TYPE 2 DIABETES: A SECONDARY ANALYSIS FROM THE CANVAS PROGRAM AND CREDENCE TRIAL', in NEPHROLOGY, WILEY, Vol. 29, pp. 75 - 75

Neuen B; Fletcher R; Arnott C; Vadagunathan M; Perkovic V; Jardine M; Neal B; Mahaffey K; Heerspink H; Pollock C, 2022, 'CANAGLIFLOZIN AND DIURETIC USE IN TYPE 2 DIABETES AND CHRONIC KIDNEY DISEASE: INSIGHTS FROM THE CREDENCE TRIAL', in NEPHROLOGY, WILEY, Vol. 27, pp. 15 - 15, http://dx.doi.org/10.26190/unsworks/28407

Tye S; Jong N; Coca SG; Sundstrom J; Arnott C; Neal B; Perkovic V; Vart P; Heerspink HJL, 2022, 'Initiation of the SGLT2 inhibitor canagliflozin to prevent kidney outcome guided by HbA_1c and predicted risk of kidney failure', in DIABETOLOGIA, SPRINGER, SWEDEN, Stockholm, Vol. 65, pp. S278 - S278, presented at 58th Annual Meeting of the European-Association-for-the-Study-of-Diabetes (EASD), SWEDEN, Stockholm, 19 September 2022 - 23 September 2022

Schechter M; Koshino A; Jongs N; Neal B; Arnott C; Perkovic V; Hansen MK; Heerspink HJL, 2022, 'Novel subgroups of patients with type 2 diabetes show differential cardiovascular and kidney benefits with canagliflozin: a data-driven proteomic cluster analysis', in DIABETOLOGIA, SPRINGER, SWEDEN, Stockholm, Vol. 65, pp. S132 - S132, presented at 58th Annual Meeting of the European-Association-for-the-Study-of-Diabetes (EASD), SWEDEN, Stockholm, 19 September 2022 - 23 September 2022, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000841795900252&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

KOSHINO A; SCHECHTER M; SEN T; NEUEN B; ARNOTT C; PERKOVIC V; HANSEN MK; HEERSPINK HL, 2022, '862-P: Interleukin-6 and Cardiovascular Outcomes in Patients with Type 2 Diabetes: A Post Hoc Analysis of CANVAS Trial', in Diabetes, American Diabetes Association, Vol. 71, http://dx.doi.org/10.2337/db22-862-p

Perkovic V; Baeres F; Bakris G; Bosch-Traberg H; Idorn T; Mahaffey K; Mann J; Mersebach H; Rossing P; Tuttle K; Pratley R, 2022, 'FC 123: Baseline Characteristics of the Flow Trial Population: Kidney Outcomes Trial With Once-Weekly Semaglutide in People With Type 2 Diabetes and Chronic Kidney Disease', in Nephrology Dialysis Transplantation, Oxford University Press (OUP), Vol. 37, pp. gfac126.002, http://dx.doi.org/10.1093/ndt/gfac126.002

Kim D; Lv J; Hladunewich M; Jha V; Hooi LS; Monaghan H; Billot L; Zhang H; Perkovic V; Wong MG, 2022, 'EFFICACY AND SAFETY OF REDUCED-DOSE ORAL METHYLPREDNISONE IN IGA NEPHROPATHY: THE TESTING TRIAL', in NEPHROLOGY, WILEY, Vol. 27, pp. 14 - 14

Feng Y; Li Q; Finfer S; Myburgh J; Bellomo R; Perkovic V; Jardine M; Wang AY; Gallagher M; Hong D, 2022, 'POS-019 A NOVEL RISK PREDICTION MODEL FOR SERVE ACUTE KIDNEY INJURY IN INTENSIVE CARE UNIT PATIENTS RECEIVING FLUID RESUSCITATION', in Kidney International Reports, Elsevier BV, Vol. 7, pp. S8 - S8, http://dx.doi.org/10.1016/j.ekir.2022.01.027

Wheeler DC; Weir MR; Gogate J; Perkovic V; Mahaffey KW, 2021, 'Effects of canagliflozin on major adverse cardiovascular events by baseline albuminuria: integrated analyses from the CANVAS Program and CREDENCE trial', in DIABETOLOGIA, SPRINGER, Vol. 64, pp. 227 - 227, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000696550100443&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Arnott C; Li JW; Cannon CP; de Zeeuw D; Neuen BL; Heerspink HJL; Charytan DM; Agarwal A; Huffman MD; Figtree GA; Bakris G; Chang TIH; Feng K; Rosenthal N; Zinman B; Jardine MJ; Perkovic V; Neal B; Mahaffey KW, 2021, 'The effects of canagliflozin on heart failure and cardiovascular death by baseline participant characteristics: Analysis of the CREDENCE trial', in Diabetes Obesity and Metabolism, Vol. 23, pp. 1652 - 1659, http://dx.doi.org/10.1111/dom.14386

Perkovic V; Rovin B; Zhang H; Kashihara N; Maes B; Rizk D; Wang W; Meier M; Kollins D; Papachristofi O; Charney A; Barratt J, 2021, 'A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL GROUP, PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LNP023 IN PRIMARY IGA NEPHROPATHY PATIENTS', in NEPHROLOGY DIALYSIS TRANSPLANTATION, OXFORD UNIV PRESS, ELECTR NETWORK, Vol. 36, pp. 160 - 160, presented at 58th Congress of the European-Renal-Association (ERA)-European-Dialysis-and-Transplant-Association (EDTA), ELECTR NETWORK, 05 June 2021 - 08 June 2021

Feng KY; Gogate J; Damaraju CV; Li J; Jardine MJ; Perkovic V; Blais JD; Pfeifer M; Neal B; Mahaffey KW, 2021, 'Canagliflozin Reduces All-cause Hospitalization in Patients with Type 2 Diabetes Mellitus', in Metabolism, Elsevier, Vol. 116, pp. 154509, http://dx.doi.org/10.1016/j.metabol.2020.154509

Mahaffey KW; Bakris G; Blais J; Cannon CP; Cherney D; Damaraju CV; Gogate J; Greene T; Heerspink HJL; Januzzi JL; Kosiborod M; Levin A; Lingvay I; Weir M; Perkovic V, 2020, 'Effects of canagliflozin on cardiovascular death and hospitalization for heart failure by baseline estimated glomerular filtration rate: integrated analyses from the CANVAS Program and CREDENCE', in European Heart Journal, Oxford University Press (OUP), Vol. 41, pp. ehaa946.3316, http://dx.doi.org/10.1093/ehjci/ehaa946.3316

Kotwal S; Mehta Y; Lee V; Mallawarchchi A; Ritchie A; Wong M; Makris A; Badve S; Yong K; Jardine M; Perkovic V; Bose B, 2020, 'GLOMERULAR DISEASE REGISTRY AND BIOBANK (GRIT)', in NEPHROLOGY, WILEY, Vol. 25, pp. 50 - 50, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000592647200150&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Mahaffey KW; Li J; Chang TI; Sarraju A; Agarwal R; Charytan DM; Greene T; Heerspink HJL; Levin A; Neal B; Pollock C; Yavin Y; Jardine M; Perkovic V; Cannon CP, 2020, 'Independent predictors of heart failure in patients with type 2 diabetes and chronic kidney disease: modeling from the CREDENCE trial', in European Heart Journal, Oxford University Press (OUP), Vol. 41, pp. ehaa946.1175, http://dx.doi.org/10.1093/ehjci/ehaa946.1175

Tiku A; Pascoe E; Boudville N; Cass A; Dalbeth N; Day RO; De Zoysa J; Douglas B; Faull R; Harris D; Hawley C; Jones GR; Kanellis J; Palmer S; Perkovic V; Rangan G; Reidlinger D; Robison L; Walker RJ; Walters G; Johnson DW; Badve S, 2020, 'THE EFFECTS OF ALLOPURINOL ON THE PROGRESSION OF CHRONIC KIDNEY DISEASE ACCORDING TO ALBUMINURIA AT BASELINE: RESULTS FROM PRE-SPECIFIED ANALYSES OF THE CKD-FIX TRIAL', in NEPHROLOGY, WILEY, Vol. 25, pp. 29 - 29, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000592647200073&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Tiku A; Pascoe E; Boudville N; Cass A; Dalbeth N; Day R; De Zoysa J; Douglas B; Faull R; Harris D; Hawley C; Jones G; Kanellis J; Palmer S; Perkovic V; Rangan G; Reidlinger D; Robison L; Walker R; Walters G; Johnson D; Badve S, 2020, 'THE EFFECTS OF ALLOPURINOL ON THE PROGRESSION OF CHRONIC KIDNEY DISEASE ACCORDING TO BASELINE SERUM URATE LEVEL: RESULTS FROM POST HOC ANALYSES OF THE CKD-FIX TRIAL', in NEPHROLOGY, WILEY, Vol. 25, pp. 60 - 61, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000592647200190&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Tiku A; Pascoe E; Boudville N; Cass A; Dalbeth N; Day R; De Zoysa J; Douglas B; Faull R; Harris D; Hawley C; Jones G; Kanellis J; Palmer S; Perkovic V; Rangan G; Reidlinger D; Robison L; Walker R; Walters G; Johnson D; Badve S, 2020, 'THE EFFECTS OF ALLOPURINOL ON THE PROGRESSION OF CHRONIC KIDNEY DISEASE ACCORDING TO DIABETIC KIDNEY DISEASE AT BASELINE: PRE-SPECIFIED ANALYSES OF THE CKD-FIX TRIAL', in NEPHROLOGY, WILEY, Vol. 25, pp. 60 - 60, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000592647200188&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Kang A; Arnold R; Gallagher M; Snelling P; Green J; Fernando M; Kiernan M; Hand S; Grimley K; Burman J; Heath A; Rogers K; Bhattacharya A; Smyth B; Bradbury T; Hawley C; Perkovic V; Krishnan AV; Jardine M, 2020, 'THE FILTRATION IN THE NEUROPATHY OF END-STAGE KIDNEY DISEASE (FINESSE) RANDOMISED CONTROLLED TRIAL', in NEPHROLOGY, WILEY, Vol. 25, pp. 11 - 11

Jun M; Jardine M; Heerspink HL; Perkovic V; Badve S; Kotwal S; Gallagher M; Harris K; Chalmers J; Woodward M, 2020, 'VARIABILITY IN EGFR AND THE RISK OF MAJOR CLINICAL OUTCOMES IN DIABETES: RESULTS FROM ADVANCE', in NEPHROLOGY, WILEY, Vol. 25, pp. 22 - 22, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000592647200049&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Heerspink HJL; Oshima M; Jardine MJ; Agarwal R; Bakris G; Charytan DM; de Zeeuw D; Levin A; Mahaffey KW; Neal B; Pollock C; Rosenthal N; Wheeler DC; Zhang H; Perkovic V, 2020, 'Acute declines in eGFR during treatment with canagliflozin and its implications for clinical practice: insights from CREDENCE', in DIABETOLOGIA, SPRINGER, ELECTR NETWORK, Vol. 63, pp. S269 - S269, presented at 56th Annual Meeting of the European-Association-for-the-Study-of-Diabetes (EASD), ELECTR NETWORK, 21 September 2020 - 25 September 2020, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000565776600560&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Mahaffey KW; Bakris G; Blais J; Cannon C; Cherney D; Damaraju CV; Gogate J; Greene T; Heerspink HJL; Januzzi JL; Kosiborod M; Levin A; Lingvay I; Weir M; Perkovic V, 2020, 'Effects of canagliflozin on cardiovascular death and hospitalisation for heart failure by eGFR: integrated analyses of the CANVAS Program and CREDENCE', in DIABETOLOGIA, SPRINGER, ELECTR NETWORK, Vol. 63, pp. S267 - S268, presented at 56th Annual Meeting of the European-Association-for-the-Study-of-Diabetes (EASD), ELECTR NETWORK, 21 September 2020 - 25 September 2020, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000565776600558&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

de Zeeuw D; Arnott C; Li J-W; Cannon CP; Neuen BL; Heerspink HJL; Neal B; Charytan DM; Bakris G; Chang T-H; Rosenthal N; Zinman B; Perkovic V; Jardine MJ; Mahaffey KW, 2020, 'The effects of canagliflozin on heart failure and cardiovascular death by baseline participant characteristics: analysis of the CREDENCE trial', in DIABETOLOGIA, SPRINGER, ELECTR NETWORK, Vol. 63, pp. S61 - S62, presented at 56th Annual Meeting of the European-Association-for-the-Study-of-Diabetes (EASD), ELECTR NETWORK, 21 September 2020 - 25 September 2020, http://dx.doi.org/10.26190/unsworks/27933

Young T; Li J-W; Kang A; Heerspink H; Hockham C; Arnott C; Neuen B; Zoungas S; Mahaffey KW; Perkovic V; De Zeeuw D; Fulcher G; Neal B; Jardine M, 2020, 'EFFECTS OF CANAGLIFLOZIN ON MAJOR ADVERSE CARDIOVASCULAR OUTCOMES IN PATIENTS WITH DIFFERENT BASELINE LEVELS OF TYPE 2 DIABETES MELLITUS DISEASE SEVERITY: RESULTS FROM THE CANVAS PROGRAM', in NEPHROLOGY DIALYSIS TRANSPLANTATION, OXFORD UNIV PRESS, ELECTR NETWORK, Vol. 35, pp. 1351 - 1351, presented at 57th Congress of the European-Renal-Association (ERA)-European-Dialysis-and-Transplant-Association (EDTA), ELECTR NETWORK, 06 June 2020 - 09 June 2020, http://dx.doi.org/10.1093/ndt/gfaa142|iii1351

Kang A; Neuen B; Heerspink HL; Di Tanna GL; Neal B; Zhang H; Hockham C; Agarwal R; Bakris G; Charytan DM; De Zeeuw D; Greene T; Levin A; Pollock C; Wheeler D; Zinman B; Mahaffey KW; Perkovic V; Jardine M, 2020, 'CANAGLIFLOZIN AND RISK OF GENITAL INFECTIONS AND URINARY TRACT INFECTIONS IN PEOPLE WITH DIABETES MELLITUS AND KIDNEY DISEASE- A POST-HOC ANALYSIS OF THE CREDENCE TRIAL', in NEPHROLOGY DIALYSIS TRANSPLANTATION, OXFORD UNIV PRESS, ELECTR NETWORK, Vol. 35, pp. 1336 - 1336, presented at 57th ERA-EDTA Congress, ELECTR NETWORK, 06 June 2020 - 09 June 2020, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000562392101381&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Kang A; Smyth B; Neuen B; Heerspink HL; Di Tanna GL; Neal B; Zhang H; Hockham C; Agarwal R; Bakris G; Charytan DM; De Zeeuw D; Greene T; Levin A; Pollock C; Wheeler D; Zinman B; Mahaffey KW; Perkovic V; Jardine M, 2020, 'CANAGLIFLOZIN AND RISK OF SKIN AND SOFT TISSUE INFECTIONS IN PEOPLE WITH DIABETES MELLITUS AND KIDNEY DISEASE - A POST-HOC ANALYSIS OF THE CREDENCE TRIAL', in NEPHROLOGY DIALYSIS TRANSPLANTATION, OXFORD UNIV PRESS, ELECTR NETWORK, Vol. 35, pp. 1342 - 1342, presented at 57th ERA-EDTA Congress, ELECTR NETWORK, 06 June 2020 - 09 June 2020, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000562392101387&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

SEN T; LI J; NEAL B; NEUEN BL; JARDINE MJ; IX J; SHLIPAK MG; PERKOVIC V; YAVIN Y; ROSENTHAL N; HANSEN MK; HEERSPINK HL, 2020, '1098-P: Biomarkers of Tubular Injury and Effects of Canagliflozin in the CANVAS Trial', in Diabetes, American Diabetes Association, Vol. 69, http://dx.doi.org/10.2337/db20-1098-p

LI J; SEN T; NEAL B; NEUEN BL; PERKOVIC V; ZEEUW DD; MAHAFFEY KW; YAVIN Y; ROSENTHAL N; HANSEN MK; HEERSPINK HL, 2020, '1120-P: Association between the Inflammatory Marker GDF-15 and Kidney Disease Progression: Results from the CANVAS Trial', in Diabetes, American Diabetes Association, Vol. 69, http://dx.doi.org/10.2337/db20-1120-p

Sarraju A; Li J; Cannon CP; Chang TI; Agarwal R; Bakris GL; Charytan DM; de Zeeuw D; Greene T; Heerspink HJL; Levin A; Neal B; Pollock C; Wheeler DC; Yavin Y; Zhang H; Zinman B; Perkovic V; Jardine M; Mahaffey KW, 2020, 'CANAGLIFLOZIN (CANA) REDUCES CARDIOVASCULAR (CV) AND RENAL EVENTS INDEPENDENT OF BASELINE HEART FAILURE (HF): A CREDENCE SECONDARY ANALYSIS', in Journal of the American College of Cardiology, Elsevier, Vol. 75, pp. 1018, http://dx.doi.org/10.1016/s0735-1097(20)31645-4

Neuen B; Mahaffey K; Cannon CP; Jardine M; Heerspink HL; Neal B; Arnott C; Zhou Z; Charytan DM; Agarwal R; Bakris GL; De Zeeuw D; Greene T; Levin A; Wheeler DC; Rosenthal N; Zhang H; Zinman B; Perkovic V; Pollock C, 2020, 'EFFECTS OF CANAGLIFLOZIN ON CARDIOVASCULAR, RENAL AND SAFETY OUTCOMES BY BASELINE LOOP DIURETIC USE: DATA FROM THE CREDENCE TRIAL', in Journal of the American College of Cardiology, Elsevier, Vol. 75, pp. 1852, http://dx.doi.org/10.1016/s0735-1097(20)32479-7

Zhou Z; Jardine M; Li Q; Lindley R; Neuen B; Cannon CP; De Zeeuw D; Edwards R; Greene T; Levin A; Mahaffey K; Perkovic V; Neal B, 2020, 'EFFECTS OF CANAGLIFLOZIN ON STROKE IN THE CREDENCE TRIAL', in Journal of the American College of Cardiology, Elsevier, Vol. 75, pp. 215, http://dx.doi.org/10.1016/s0735-1097(20)30842-1

Perkovic V; Bain SC; Bakris G; Buse JB; Gondolf T; Idorn T; Lausvig N; Mahaffey K; Marso SP; Nauck MA; Pratley R; Rossing P; Zinman B; Mann J, 2019, 'Estimated GFR (eGFR) loss with glucagon-like peptide-1 (GLP-1) analogue treatment: data from SUSTAIN 6 and LEADER', in DIABETOLOGIA, SPRINGER, SPAIN, Barcelona, Vol. 62, pp. S484 - S485, presented at 55th Annual Meeting of the European-Association-for-the-Study-of-Diabetes (EASD), SPAIN, Barcelona, 16 September 2019 - 20 September 2019

Neal B; Li J; Perkovic V; Woodward M; Figtree GA; Heerspink HL; Mahaffey KW; de Zeeuw D; Vercruysse F; Shaw W; Matthews DR, 2019, 'An exploration of factors mediating the effects of canagliflozin on heart failure in patients with type 2 diabetes', in DIABETOLOGIA, SPRINGER, SPAIN, Barcelona, Vol. 62, pp. S343 - S343, presented at 55th Annual Meeting of the European-Association-for-the-Study-of-Diabetes (EASD), SPAIN, Barcelona, 16 September 2019 - 20 September 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000485303803044&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Neuen BL; Perkovic V; Ohkuma T; Neal B; Matthews DR; de Zeeuw D; Mahaffey KW; Fulcher G; Oh R; Li Q; Jardine M, 2019, 'Canagliflozin in patients with type 2 diabetes and macroalbuminuria: data from the CANVAS program', in DIABETOLOGIA, SPRINGER, SPAIN, Barcelona, Vol. 62, pp. S341 - S342, presented at 55th Annual Meeting of the European-Association-for-the-Study-of-Diabetes (EASD), SPAIN, Barcelona, 16 September 2019 - 20 September 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000485303803041&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Mahaffey KW; Li J; Badve SV; Zhou Z; Oh R; Lee M; Perkovic V; de Zeeuw D; Fulcher G; Matthews DR; Neal B, 2019, 'The effects of canagliflozin on uric acid and gout in patients with type 2 diabetes in the CANVAS programme', in DIABETOLOGIA, SPRINGER, SPAIN, Barcelona, Vol. 62, pp. S340 - S341, presented at 55th Annual Meeting of the European-Association-for-the-Study-of-Diabetes (EASD), SPAIN, Barcelona, 16 September 2019 - 20 September 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000485303803039&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Perkovic V; Bain S; Bakris G; Buse J; Idorn T; Mahaffey K; Marso S; Nauck M; Pratley R; Rasmussen S; Rossing P; Tornoe K; Zinman B; Mann J, 2019, 'EFFECTS OF SEMAGLUTIDE AND LIRAGLUTIDE ON URINARY ALBUMIN-TO-CREATININE RATIO (UACR) - A POOLED ANALYSIS OF SUSTAIN 6 AND LEADER', in NEPHROLOGY DIALYSIS TRANSPLANTATION, OXFORD UNIV PRESS, HUNGARY, Budapest, Vol. 34, pp. 205 - U715, presented at 56th Congress of the European-Renal-Association (ERA)-European-Dialysis-and-Transplant-Association (EDTA) - Burden, Access and Disparities in Kidney Disease, HUNGARY, Budapest, 13 June 2019 - 16 June 2019

Perkovic V; Bain S; Bakris G; Buse J; Idorn T; Mahaffey K; Marso S; Nauck M; Pratley R; Rasmussen S; Rossing P; Tornoe K; Zinman B; Mann J, 2019, 'EFFECTS OF THE GLUCAGON-LIKE PEPTIDE-1 (GLP-1) ANALOGUES SEMAGLUTIDE AND LIRAGLUTIDE ON RENAL OUTCOMES - A POOLED ANALYSIS OF THE SUSTAIN 6 AND LEADER TRIALS', in NEPHROLOGY DIALYSIS TRANSPLANTATION, OXFORD UNIV PRESS, HUNGARY, Budapest, Vol. 34, pp. 338 - 338, presented at 56th Congress of the European-Renal-Association (ERA)-European-Dialysis-and-Transplant-Association (EDTA) - Burden, Access and Disparities in Kidney Disease, HUNGARY, Budapest, 13 June 2019 - 16 June 2019

Perkovic V; Bain S; Bakris G; Buse J; Gondolf T; Idorn T; Lausvig N; Mahaffey K; Marso S; Nauck M; Pratley R; Rossing P; Zinman B; Mann J, 2019, 'EGFR LOSS WITH GLUCAGON-LIKE PEPTIDE-1 (GLP-1) ANALOGUE TREATMENT: DATA FROM SUSTAIN 6 AND LEADER', in NEPHROLOGY DIALYSIS TRANSPLANTATION, OXFORD UNIV PRESS, HUNGARY, Budapest, Vol. 34, presented at 56th Congress of the European-Renal-Association (ERA)-European-Dialysis-and-Transplant-Association (EDTA) - Burden, Access and Disparities in Kidney Disease, HUNGARY, Budapest, 13 June 2019 - 16 June 2019

Back to profile page